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Abstract
Objective The aim of this study was to investigate the
relation between Cathepsin D (Cath-D) and E-Cadherin
(E-Cad) expression levels in tumor tissue and neck lymph
node metastasis. This attempt should be made to identify
new factors that one could be useful in predicting clinical
behavior.
Study design In this study, we investigated rates of dying
for E-Cad and Cath-D in paraphin blocks of larynx and
neck dissection specimens taken from 56 selected patients.
Laryngeal specimens dyed by ECad and Cath-D immuno-
histochemically. Immunoreactivity classiWed for E-Cad as
positive (75% and above), reduced (25–75%) and negative
(below 25%). Immunoreactivity classiWed for Cath-D:dye
absorption rates higher than 50% evaluated positive and
absorption rates lower than 50% evaluated negative. We
compared the rates of dying for E-Cad and Cath-D groups
to with or without neck lymph node metastasis in speci-
mens.
Results Neck metastasis were found in 41% of patients, in
55.6% of patients, if the E-Cad was negative, 40.6% if it
was reduced, 33.3% if it was positive in specimens. The
neck metastasis was found in 35.4% of patients with Cath-
D expression negative, while 75% of patients was found
with Cath-D expression positive.
Conclusion Neck metastasis was found higher in E-Cad
reduced group than positive group. Neck node metastasis
was signiWcantly higher in Cath-D positive group than
Cath-D negative group. Cath-D and E-Cad essays may use-
ful in identifying neck lymph node involvement. Cath-D
expression levels are more in this predictive factor than
E-Cad levels for possibility of neck lymph node metastasis
in LSCC.
Keywords Cathepsin D · E-Cadherin · Lymph node 
metastasis · Laryngeal carcinoma
Introduction
Laryngeal carcinoma accounts for 2–3% of all annual diag-
nosed cancers in the world (Jemal et al. 2004). The prog-
nostic clinical characterization of LSCC remains
inadequate because the outcome may diVer considerably in
comparably staged and treated patients (Pera et al. 1986).
Currently, in LSCC tumor, behaviors and applied treat-
ments, according to TNM and histological staging system,
have managed. But diVerent results of treatments are taken
at the same age, stage and localizations in resemble
patients; it shows some insuYciency of these classiWca-
tions. According to these Wndings, we decided to investi-
gate new prognostic factors and some new revaluations in
clinic assessment.
Exception of distant metastasis, the presence of cervical
lymph node metastasis, is the single most adverse indepen-
dent prognostic factor. It decreases the overall survival
approximately 50% and decreases the survival of more than
50% if extra capsular expansion exists (Jemal et al. 2004;
Johnson and Myers 1991; Richard et al. 1987). Certain
cervical lymph node metastasis assessment is diYcult in all
patients (Johnson and Myers 1991; Richard et al. 1987;
Moe et al. 1996). The probability of positive lymph node in
neck specimens in patients has found 13, 7–37% with non-
palpable lymph node by examination (N0) (Kirchner and
Carter 2004). We need better methods that could identify
clinical behavior to predict lymph node metastasis, invasion
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primary tumor with lymph node micro metastasis for addi-
tion of neck dissection (Harrison and Thawley 1987). This
situation correlates with clinic-pathologic characteristics of
the tumor (Schipper et al. 1994). Molecular membranous
labeling in metastatic cells may be useful for illustration of
lymph node metastasis (Richard et al. 1987; Schantz 1994).
Currently, it is investigated that the prognostic values of
many tumor markers in immunohistochemical and molecu-
lar techniques like proteases, oncogene products, peptide
growth factors (EGF and EGFR) and their eVect of tumor
invasion and metastasis in LSCC (Almadori et al. 2005;
Vignon et al. 1982).
Degradation of basal membrane is the Wrst attack of the
carcinoma cells. There are some proteases eVecting these
procedures (Johnson and Myers 1991). Cathepsin D
(Cath-D) is a well-known ones found in 1980, an aspartyl
endopeptidase that, apart from its involvement in tumor
invasion as a proteolytic enzyme, secreted from cancer
and stromal cells has also been demonstrated to have a
mitogenic eVect in vitro, which suggests that elevated
Cath-D levels may be associated with abnormal cell
growth and it plays a role in basal membrane digestion
and break down (Vignon et al. 1982). Elevated Cath-D
levels in tissue increases angiogenic secretions causes’
neovascularization, increases the transport and invasion
of tumor cells and metastasis takes place easily (Isola
et al. 1993; Leto et al. 1992).
The other important factor of tumor invasion is the
Cadherin, a cell-surface glycoprotein’s that act as inter-
cellular adhesion molecules through calcium-dependent
binding, which mediate predominantly homotypic cell–
cell interactions and play a key role during morphogene-
sis, as well as in the maintenance of the diVerentiated phe-
notype. E-Cadherin (E-Cad) is expressed in the lower
spinous and basal cell layer (Richard et al. 1987). It is also
involved in the transduction of signals controlling various
cellular events, including polarity, diVerentiation, growth
and cell migration (Johnson and Myers 1991). Loss of or
reduction in E-Cad protein expression has been associated
with increased invasiveness, advanced T and N stages and
unfavorable prognosis (Shinohara et al. 1998). Its expres-
sion protected in well-diVerentiated cancers, which main-
tain their cell–cell adhesiveness and are less invasive, but
reduced in undiVerentiated cancers, which have lost their
cell–cell adhesion and show a strong invasive tendency
(Lee 1996).
We investigated the relation of neck lymph node
involvement and the stromal expression levels of the E-Cad
which mediated intercellular adhesion in epithelium and
Cath -D, which cause degradation of basal membrane by
using immunohistochemical techniques in LSCC in this
study. The prognostic implications of changes in expression
levels of these two markers are compared and evaluated in
relation to neck node metastasis.
Patients and methods
This study included 51 men and 5 women, a total of 56
patients aged from 38 to 85 years (mean age: 55.9 years),
who were diagnosed and treated for LSCC. All patients has
only one primer tumor and no one had received another
treatment.
Their tumors were staged according to the TNM system
of the International Union Against Cancer (IUAC 4th
edition), after surgical resections. Early staged tumors like
T1 treated without neck node dissection were excluded in
this study.
Their surgical resection and neck node dissections were
performed on patients with histological and existence or
highly possible neck lesions with T2 or locally advanced
stage T3-4 on surgical Wndings. The stage of patient’s
tumors in T classiWcation was as follows: 22 patients with
T2, 24 patients with T3, 10 patients with T4.
All Patient had 4 well-diVerentiated, 44 moderate and 8
less diVerentiated tumors. Two of the tumor localizations
were glottosubglottic, 24 of them glottosupraglottic, 16 of
them supraglottic, 14 of them transglottic.
All patients received neck dissections bilaterally. Totally
112 neck dissections were applied as to 9 radical, 33 func-
tional, 2 type II modiWed radical and 68 selective neck dis-
sections on the operations.
The paraYn blocks and pathologic materials were
selected from surgical larynx and neck dissection speci-
mens of the patients. Methastasis positive and negatives
patients were determined in neck node dissection materi-
ales. Neck node methastasis was found in 23 of patients as
in 6 of them T2, 13 of them T3 and 4 of them T4.
Laryngeal specimens dyed speciWcally for E-Cad and
Cath-D immunohistochemical dye diVerently. Patients clas-
siWcated and compared to their specimens according to dye
taken in rates and lymph node involvement.
Dying formation classiWed in three groups for E-Cad as
immunoreactivity preserved or positive (75 and up%),
reduced (25–75%) and negative (lower than 25%).
Dying formation classiWed in two groups for Cath-D as
dye absorption rates over 50% of the observation area eval-
uated a positive, Cath-D group lower than 50% of the
observation area evaluated negative Cath-D groups.
We compared the rates of dying E-Cad and Cath-D
groups to, with or without neck lymph node metastasis in
specimens. The eVectiveness of neck lymph node metasta-
sis of E-Cad, which causes intercellular adhesion, and
Cath-D, which causes degradation of basal membrane,
evaluated together and diVerently for the lymph node123
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same study.
Immunohistochemical study
Tissue specimens were collected during surgery, and the
formalin-Wxed paraYn-embedded tissues were cut into
2 m sections and dried on capillary-gap glass slides.
Two diVerent immunohistochemical markers for study-
ing twice, section adhesive glass slides were taken.
After spoiled, excessive block solution without washing
for primer antibody E-Cad (monoclonal Mouse Antihuman
E-Cad: NCH-38 DakoCytomation- USA) or Cath-D (mono-
clonal Mouse Antihuman Cath- D: SCI 13148 Santa Cruz
Biotechnology-USA) was dropped. Staining was done at
room temperature, slides were placed for 2 h and then the
samples were washed with PBS 3 times for 5 min. E-Cad
showed membranous labeling in all the cells in the lower
half of the normal squamous epithelium used as a positive
control. Hence, only this half was considered to give the
staining score of the normal mucosa surrounding the
tumor. Cath-D and E-Cad immunoreactivity images were
acquired using an Olympus BX40 microscope, random-
ized, without clinic data and evaluated from two indepen-
dent observers. Appropriate positive controls were used
(normal laryngeal epithelium). Negative controls with an
omission of the antiserum from the primary incubation
were also included. Immunostaining was done only in
tumor parenchymal and stromal cells (well staining) far
away tissue damages and necrosis. Cath-D immunostain-
ing analyses were done in epithelium cell reactions. The
staining was predominantly membranous with some cyto-
plasmatic staining. A staining score was given based on
the percentage of cells stained (0–100%). A score was
given for both the tumor and the surrounding normal-
appearing epithelium. Cath-D expression was classiWed in
two groups as epitel, immunostaining rates higher than
50% and lower than 50% observing the surface of tumors
area (Goussia et al. 1999) (Figs. 1, 2). If E-Cad expression
were classiWed in three groups as epitel cells, immuno-
staining rates have shown 75% or more immunostaining
were evaluated as preserved or positive; 25–75% reduced
staining; lower than 25% evaluated negative staining of
the cell in the observing the surface of tumors area (Liu
et al. 1997) (Figs. 3, 4).
Statistical analysis
Statistical analysis was performed by SPSS (Statistical
Package for Social Sciences) for Windows 11.5. Distribu-
tion of Cath-D and E-Cad levels according to clinic-patho-
logical parameters was analyzed by chi-square tests, and it
was given standard deviations presumed, categorical
changing parameters frequency and percents when evalu-
ated study data of measurement changes, averaged, mean
scores.
Fig. 1 Cathepsin D expression higher than 50% in case (magniWca-
tion, £40)
Fig. 2 Cathepsin D expression lower than 50% in case (magniWcation,
£40)
Fig. 3 Patients with tumors E-Cadherin immunoreactivity rates high-
er than 75% named protected (magniWcation, £40)123
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cal parameters were analyzed by Pearson chi-square and
Fisher’s exact test. Staining scores were averaged for each
group, and mean scores were compared within groups with
respect to clinic-pathological parameters as the presence
of cervical lymph node metastasis within the overall
group.
To investigate whether a combination of parameters was
more predictive for the nodal status than a single parameter,
stepwise logistic regression analysis was performed using
the variables that showed signiWcant correlation with
metastases in the univariate analysis.
Statistical signiWcance was taken of 95% conWdence
intervals in the estimation of results, P < 0.05. P values of
<0.05 were considered to be statistically signiWcant.
Results
Forty-one percentage of the patients (n = 23/56) had clini-
cally positive neck nodes in their therapeutic neck dissec-
tions specimens.
The stage of patients’ tumors in TNM classiWcation was:
22 patients (39.3%) with T2, 24 patients (42.9%) with T3,
10 patients (17.9%) with T4.
T stages of patients evaluated that the metastatic neck
lymph node were found in 6/22 (27.3%) of patients with
T2, 13/24 (54.2%) of patients with T3, 4/10 (40%) of
patients with T4.
Patients with Cath-D expression rate less than 50%
named negative group were found 85.7% of all and higher
than 50% named positive group were found 14.3% of all.
The metastatic neck lymph nodes were found in 75% of
patients if Cath-D expression was positive and 35.4% of
patients if Cath-D expression was negative.
Patients with tumors E-Cadherin immunoreactivity rates
lower than 25% named negative were found 16.1%,(25–75%)
named reduced 57.1%, (75%-up) named protected 26.8%
of all, respectively.
Neck node metastasis was found positive in 55.6% of all
if E-Cad was negative; 40.6% of all if E-Cad was reduced
and 33.3% of all if E-Cad protected.
Cath-D expression levels positive and E-Cad levels neg-
ative were found in 3.6%, reduced 8.9%, protected 1.8% of
all cases. Their neck node metastasis rates were found in
100, 80 and 0% of all, respectively (Table 1).
Cath-D expression levels negative and E-Cad levels
negative were found in 12.5% of all, reduced 48.2%, pro-
tected 25% of all cases. Their neck node metastasis rates
were found in 42.9, 33.3 and 35.7% of all, respectively
(Figs. 5, 6).
Cath-D expression levels positive, E-Cad levels negative
and T4 tumors were found as a prognosis deteriorating fac-
tors in LSCC. They were found 14.3, 16.1 and 17.9% of
patients with LSCC, respectively. Their neck node metasta-
sis rates were found 75, 55.6 and 40%, respectively. This
rates apparently high with the other groups. We can say that
Cath-D expression levels positivity, E-Cad levels negativity
and T4 tumors are as a prognosis deteriorating factors in
LSCC.
E-Cad levels can determined or obviously eVect neck
metastasis rates. But the relation E-Cad expression and
metastatic cervical lymph node were not found signiWcant
statistically (Fisher’s Exact Test; P = 0.157).
Fig. 4 Patients with tumors E-Cadherin immunoreactivity rates lower
than 25% named negative (magniWcation, £40)
Table 1 The clinic-pathological features of the patients
The metastatic neck lymph nodes rates were found in patients accord-





n (%) n (%)
T1 – – – –
T2 22 39.3 6 27.3
T3 24 42.8 13 54.2
T4 10 17.9 4 40
Cath-D + (50% and up) 8 14.3 6 75
Cath-D ¡ (Lower than 50%) 48 85.7 17 35.4
E-Cath 25% (negative) 9 16.1 5 55.6
E-Cath 25–75% (reduced) 32 57.1 13 40.6
E-Cath 75% (protected) 15 26.8 5 33.3
Cath-D + E-Cath 25% 2 3.6 2 100
Cath-D + E-Cath 25–75% 5 8.9 4 80
Cath-D + E-Cath 75% 1 1.8 0 0
Cath-D ¡ E-Cath 25% 7 12.5 3 42.9
Cath-D ¡ E-Cath 25–75% 27 48.2 9 33.3
Cath-D ¡ E-Cath 75% 14 25 5 35.7123
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eVect neck metastasis rates.
We found a signiWcant relationship between Cath-D rate,
increasing and neck lymph node positivity (N+) at presen-
tation (Fisher’s Exact Test; P = 0.053).
Discussion
The management of regional lymph nodes in the neck is
important because of the decrease in the overall survival
approximately 50% (Andersen et al. 1994). With the excep-
tion of distant metastases, the presence of cervical lymph
node metastasis is the single most adverse independent
prognostic factor in the head and neck SCC (Suen and Stern
1996). Five-year survival is as 29–54% in (N+), but this is
65–94.5% in N(0) patients (Cotran et al. 1994).
Palpation has been reported to detect about 70% of
cervical metastasis in the clinical examination with palpa-
tion. In LSCC with clinically N0 neck probability of lymph
node metastases is found 13.6–37% in surgical specimens
(Kirchner and Carter 2004; Takes et al. 1997). Molecular
and immunohistochemical tumor markers help to determine
cancer in risk bearing patients and areas of larynx mucosa.
Cancer markers also show which drugs and targets we have
to use in prophylactic treatment (Almadori et al. 2005). It is
ideal to treat only the patients who had really occult metas-
tases of the neck. Current technology is not compatible to
determine for early occult metastasis without histopatholo-
gical evaluation.
We investigated the eVect of the immunohistochemical
expression of E-Cad, which inhibits the tumor invasion and
Cath-D, which provoked the tumor invasion on metastases
of the neck in this study. It is possible that some patients
with reduced E-Cad expression show subclinical cervical
metastasis at the moment of diagnosis of the primary
tumor, which would explain the association between this
reduced expression and the higher incidence of regional
relapses and disease free period (Shinohara et al. 1998).
Some studies have demonstrated a correlation between
reduced E-Cad expression and nodal metastases tumor
stage, grade of diVerentiation, invasiveness, lymph node
involvement and distant metastases (Schipper et al. 1994;
Bukholm et al. 1998; Lim et al. 2004). It was suggested that
it was the best independent predictor of the appearance of
cervical metastasis and found to be protected in well- and
moderately diVerentiated cancers, but reduced or lost in
undiVerentiated cancers (Schipper et al. 1994; Shinohara
et al. 1998).
Another investigators could not Wnd any signiWcant asso-
ciation between the degree of diVerentiation and E-Cad
expression; however, they found that patients with reduced
E-Cad expression in tumors showing higher invasiveness or
cervical lymph node metastasis (Liu et al. 1997; Bagutti
et al. 1998) and lost of the E-Cad expression in tumor cells
in invasion area (Rodrigo et al. 2003) Chang et al. observed
reduced E-Cad expression in 83% of their cases of carci-
noma of the tongue. The prognosis in this subset of patients
was signiWcantly poorer than in the remaining patients
(Chang et al. 2002). However, some studies have failed to
show a relationship between E-Cad expression and these
clinic-pathological variables (Takes et al. 1997; Bowie
et al. 1993; Andrews et al. 1997).
We found 41% lymph node metastases in all cases. The
E-Cad expression was found to reduce in 57.1% of cases
and negative in 16.1% of cases, when added together in
73.2% of cases with LSCC. The signiWcant association
Fig. 5 The metastatic neck lymph nodes rates were found in patients
according to Cathepsin D, E-Cadherin expression levels and T stages
Fig. 6 The metastatic neck lymph nodes rates were found in patients
according to Cathepsin D, E-Cadherin expression levels and T stages123
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the presence of cervical metastasis, when reduced (40.6%)
and negative (55.6%), in total reduced groups (43 9%)
compared to protected groups (33.3%). However, it was not
statistically signiWcant. Analysis indicated and conWrmed
that reduced or absent E-Cad expression was associated
with high relation with cervical lymph node metastasis. E-Cad
expression may play a role in the decision to treat a N0
neck with a neck dissection or with close follow-up (in
addition to other factors like T-stage, histological diVerenti-
ation, age and co-morbidity). These results were similar to
those of Tanaka et al. 2003.
Cath-D expression was demonstrated in normal and
cancerous tissues but more so dying in cancerous area
compared to noncancerous area. Increasing of Cath-D
expression not only speciWc for laryngeal tumors but also
seen in ovarian, endometrial and breast carcinomas. The
total concentration of Cath-D was a signiWcant independent
factor for identifying breast cancer patients with poor prog-
nosis and at high risk of lymph node metastatic disease
(Spyratos et al. 1989). There is not too much study on
investigating Cath-D expression as immunohistochemical
in laryngeal lesions. It has been known to eVect this
enzymes for lymph node but also it is not instutied any rela-
tion with the amount of Cath-D and lymph node metastasis
(Lazaris et al. 2000). Andreas et al. suggested that the pos-
sibility involvement in the process of tumor spread but the
concentrations of Cath-D did not correlate with survival,
relapse-free survival for Cath-D immune status (Maurizi
et al. 1996). Maurizi et al. have found a relation with
increased Cath-D expression and recurrent laryngeal carci-
noma and take role in tumor inWltration compared to other
lesions. It has increased mainly in laryngeal CA compared
to normal mucosa (Goussia et al. 1999). If it has found a
higher rate in tumor tissue, it will be able to take a role in
tumor metastasis (Maurizi et al. 1996). Hence they did not
Wnd a relation with clinic histopathological sign (TNM,
recurrence, grade) (Smid et al. 1997).
We found increased Cath-D expression levels in 14.3%
of case with LSCC. When it increased to 50% or higher,
concentration of tissue associated with neck lymph node
involvement at clinical presentation as 75%. This Wnding
suggests that Cath-D concentration is a signiWcant indepen-
dent prognostic factor for identifying LSCC patients at high
risk of neck node metastasis. This is similar Diniz and
Spyratos et al. Wndings, which was conWrmed as a clear
association between high cytosolic Cath-D and an
increased metastatic potency of tumor cells of laryngeal
cancer patients with a high risk of metastatic neck node
involvement, similar to what happens in breast cancer
(Spyratos et al. 1989; Diniz-Freitas et al. 2006).
Our results suggest that assessment of Cath-D and E-Cad
status at the time of initial surgery may identify a subset of
laryngeal cancer patients with increased metastatic potency
and permit therapy to be adapted accordingly. Patients
bearing tumors with high Cath-D and reduced E-Cad levels
should undergo elective neck dissection, elective neck irra-
diation or post-surgical irradiation for neck lymph node
metastasis even without extra nodal spread.
It shows that the risk of lymph node metastasis increases
with Cath-D and reduced E-Cad values in a signiWcant way.
These data agree with the Wndings of Tandona et al. 1990
and Maudelonde et al. 1990.
Conclusion
Reduction in E-Cad expression and high Cath- D concen-
tration in LSCC is a predictor for lymph node metastases.
Together with other clinical and histological indicators, it
can be considered a useful marker of poor prognosis in
patients with LSCC.
Cath-D and E-Cad. expressions can determine at the Wrst
diagnostic biopsy in these patients. Their immunohisto-
chemical determination might be useful in identifying
patients with clinically negative lymph nodes. Assessment
of Cath-D and E-Cad expression status at the time of initial
surgery may identify a subset of laryngeal cancer patients
with increased metastatic potency and therapy to be
adapted accordingly.
Patients bearing tumors with high Cath-D and low E-Cad
levels may carry a considerable risk for occult metastases
and should undergo elective neck dissection or additional
therapy. These two markers are a reliable indicator of
increased tumor invasiveness in LSCC.
Further prospective trials are required to conWrm the role
of E-Cad and Cath- D expression in predicting the behavior
of these neoplasms.
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